Head and Neck Cancer
Conditions
Brief summary
A retrospective chart review of patients receiving concurrent chemoradiotherapy for oropharynx cancer was performed to compare clinical data for patients treated prior to the initiation of the NP clinic with those subsequently seen weekly in the NP clinic. The variables studied included; rate of hospitalization, dose completion and dose reductions. The results revealed an overall improvement in all variables for those patients seen in the weekly NP clinic. To further analyze this data a randomized, prospective study is proposed to validate the findings of the retrospective study. It is predicted that a weekly NP led clinic will decrease costly hospitalizations, increase patient treatment completion and improve overall patient quality of life and satisfaction.
Interventions
OTHERNurse Practitioner Clinic
The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment. Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs.
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a diagnosis of stage III or IV HNC * Are initiating concurrent chemotherapy and radiation * Are able and willing to sign informed consent * Ages 18 years or older * ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 (The ECOG score attempt to quantify cancer patients' general well-being and activities of daily life) * Able to read and complete the required survey
Exclusion criteria
* Cannot provided informed consent * Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment. * Have a history of prior cancer within past 5 years (excluding non-melanoma skin cancer) * Are unwilling or unable to complete the required QOL (Quality of Life) survey
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients that Experience a Problem during Cancer Treatment | 11 weeks | A problem includes any one of three events: dose reduction, inability to complete treatment, or toxicity related hospitalization. Patients are assigned a 1 if any of these events occurs at least once during treatment or are assigned 0 if they complete treatment with no dose reductions or toxicity related hospitalizations. When data is analyzed and reported, the problem rate will be summarized along with the each individual negative component. |
Countries
United States
Outcome results
None listed